What this is
- How it works
- How it works isn't classified yet
- Tested for
- COVID-19 Infection, Hematopoietic and Lymphoid System Neoplasm, Leukemia, Lymphoma, Plasma Cell Myeloma
- Main trialPhase 2
- “This phase 2 trial studies the immune response to GEO-CM04S1 (previously designated as COH04S1) compared to standard of care (SOC) mRNA SARS-COV-2 vaccine in patients with blood cancer who have received stem cell transplant or cellular therapy. GEO-CM04S1 belongs to a category called modified vaccinia Ankara (MVA) vaccines, created from a new version of MVA, called synthetic MVA. GEO-CM04S1 works by inducing immunity (the ability to recognize and fight against an infection) to SARS-CoV-2. The immune system is stimulated to produce antibodies against SARS-CoV-2 that would block the virus from…”In the company’s words, NCT04977024 on ClinicalTrials.gov
- Other names
- GEO-CM04S1
Other drugs for COVID-19 Infection
- MaravirocHealthBio, Inc. · Phase 2/3
- REGENECYTEStemCyte, Inc. · Phase 3
- VYD2311Invivyd, Inc. · Phase 3
- SecutrelvirShionogi · Phase 3
- IbuzatrelvirPfizer · Phase 3
- TozorakimabAstraZeneca · Phase 3
Coming up1
- 31 DecPhase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | 31 Dec 2026 | SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer | |
| Phase 1/2Completed | 31 Oct 2025 | A Synthetic MVA-based SARS-CoV-2 Vaccine, GEO-CM04S1, for the Prevention of COVID-19 Infection |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026